Uncategorized
Arcturus Prunes Early-Stage Pipeline to Focus on mRNA Therapies
Arcturus Therapeutics; pipeline reduction; mRNA therapies; cystic fibrosis; ornithine transcarbamylase deficiency; Kostaive; vaccine programs; biotech strategy; cash runway
Bayer Restructuring Cuts 2,000 Jobs, Thins Management Layers in 2025
Bayer; restructuring; job cuts; management layers; layoffs; Frankfurt plant closure; pharmaceutical industry
RFK Jr. Defends HHS Staff Cuts and Reorganization at House and Senate Hearings
RFK Jr.; HHS; staff cuts; reorganization; Congress; House Appropriations Committee; Senate HELP Committee; budget cuts; Medicaid; health coverage
Organon Launches ‘Romantasy’-Inspired Nexplanon Ad Campaign
Organon; Nexplanon; romantasy; ad campaign; birth control; pharmaceutical marketing; women’s health; fantasy-romance; contraceptive implant
Merck’s Keytruda Achieves Industry-First Success in Preventing Head and Neck Cancer Recurrence: AACR 2025 Highlights
Keytruda; Merck; AACR 2025; head and neck cancer; resectable locally advanced head and neck squamous cell carcinoma; event-free survival; KEYNOTE-689 trial; perioperative pembrolizumab; recurrence prevention; clinical trial; FDA
GSK and iTeos End Belrestotug TIGIT Program After Disappointing Lung Cancer Results
GSK; iTeos; belrestotug; TIGIT; lung cancer; dostarlimab; clinical trial; drug development; GALAXIES Lung-201; immuno-oncology; progression-free survival
OpenAI Debuts HealthBench Dataset to Evaluate AI Models in Real-World Medical Scenarios
OpenAI; HealthBench; AI healthcare benchmark; large language models; medical AI evaluation; physician rubrics; realistic medical scenarios; AI safety; open-source dataset
Galapagos Walks Back Split Plans, Raising Questions Over Cell Therapy Assets
Galapagos; company split; cell therapy; spinoff; CEO appointment; biotech industry; CAR T business
UnitedHealth Group CEO Andrew Witty Steps Down; Stephen Hemsley Returns as CEO
UnitedHealth Group; Andrew Witty; Stephen Hemsley; CEO transition; leadership change; personal reasons; financial guidance suspension; stock drop
Federal Appeals Court Revives CRISPR Patent Dispute Between Broad Institute and University of California
CRISPR; patent dispute; Broad Institute; University of California; Federal Circuit; PTAB; gene editing; intellectual property; eukaryotic cells